Cargando…

An exploration of LAF‐bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non—small cell lung cancer

BACKGROUND: Immune checkpoint inhibitor (ICI) combined with chemotherapy is one of the standards of care for advanced non–small cell lung cancer (NSCLC) without driver mutations. However, the biomarker of combination therapy is still unknown. Although previous studies have confirmed that low allele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shuyang, Yang, Lu, Yang, Yaning, Xin, Ying, Wang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715764/ https://www.ncbi.nlm.nih.gov/pubmed/36274215 http://dx.doi.org/10.1111/1759-7714.14696

Ejemplares similares

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China
por: Yang, Guangjian, et al.
Publicado: (2022)

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
por: Jiang, Tao, et al.
Publicado: (2022)

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
por: Hodi, F. Stephen, et al.
Publicado: (2021)

Exploring the prognostic function of TMB-related prognostic signature in patients with colon cancer
por: Zhao, Yan, et al.
Publicado: (2023)

TMB in NSCLC: A Broken Dream?
por: Bravaccini, Sara, et al.
Publicado: (2021)

LAF: Logic Alignment Free and its application to bacterial genomes classification
por: Weitschek, Emanuel, et al.
Publicado: (2015)

Regulatory roles of Bxy-laf-1 in reproductive behaviour of Bursaphelenchus xylophilus
por: Sun, Shimiao, et al.
Publicado: (2022)

Identifying Inconsistencies and Reporting Deficits in Therapeutic Massage and Bodywork (TMB) Case Reports Authored by TMB Practitioners: a TMB-Adapted CAse REport (CARE) Guidelines Audit Through 2014
por: Munk, Niki, et al.
Publicado: (2016)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB
por: Miao, Xia-ye, et al.
Publicado: (2022)

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
por: Sung, Meng-Ta, et al.
Publicado: (2022)

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice
por: Yang, Yaning, et al.
Publicado: (2022)

Longitudinal conductivity of LaF(3)/SrF(2) multilayer heterostructures
por: Vergentev, Tikhon, et al.
Publicado: (2016)

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs
por: Yang, Lu, et al.
Publicado: (2020)

Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer
por: McCann, Katy, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

LAFS: a learning-based adaptive forwarding strategy for NDN-based IoT networks
por: Djama, Adel, et al.
Publicado: (2021)

PathwayTMB: A pathway-based tumor mutational burden analysis method for predicting the clinical outcome of cancer immunotherapy
por: Li, Xiangmei, et al.
Publicado: (2023)

Spectroscopy of single Pr(3+) ion in LaF(3) crystal at 1.5 K
por: Nakamura, Ippei, et al.
Publicado: (2014)

The Lipoteichoic Acid-Related Proteins YqgS and LafA Contribute to the Resistance of Listeria monocytogenes to Nisin
por: Pang, Xinxin, et al.
Publicado: (2022)

Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB
por: Fridland, Stanislav, et al.
Publicado: (2021)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

The prognostic value of TMB in early-stage non-small cell lung cancer: a systematic review and meta-analysis
por: Wankhede, Durgesh, et al.
Publicado: (2023)

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer
por: Chen, Dongna, et al.
Publicado: (2023)

Implementing TMB measurement in clinical practice: considerations on assay requirements
por: Büttner, Reinhard, et al.
Publicado: (2019)

What makes TMB an ambivalent biomarker for immunotherapy? A subtle mismatch between the sample-based design of variant callers and real clinical cohort
por: Liu, Yuqian, et al.
Publicado: (2023)

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
por: Palmeri, M., et al.
Publicado: (2021)

1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants
por: Towner, William, et al.
Publicado: (2020)

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

The safety and efficacy of chemotherapy combined with immunotherapy for pancreatic cancer: A meta-analysis
por: Huang, Yang, et al.
Publicado: (2021)

The impact of subsidized low aromatic fuel (LAF) on petrol (gasoline) sniffing in remote Australian indigenous communities
por: d’Abbs, Peter, et al.
Publicado: (2017)

Computer Modelling of Energy Structure of Yb(3+) and Lu(3+) Doped LaF(3) Crystals
por: Chornodolskyy, Yaroslav, et al.
Publicado: (2022)

Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors
por: Zhang, Zhengfeng, et al.
Publicado: (2023)

Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f3k6tk6v1h2mq21sbnjl8ecgdo